Steady-state kinetics of valproic acid in epileptic patients
- PMID: 357068
- DOI: 10.1002/cpt1978243324
Steady-state kinetics of valproic acid in epileptic patients
Abstract
Pharmacokinetic evaluation and prediction were carried out in 20 epileptic patients. Using conventional pharmacokinetic techniques and a one-compartment model, predicted and observed valproic acid plasma concentrations were compared. Valproic acid assay was performed by gas-liquid chromatography. There was good agreement between predicted and observed plasma concentrations. Most patients had predicted half-lives (t1/2s) of 6 to 8 hr, independent of the plasma concentration of valproic acid. Five patients had predicted t1/2s of 12 hr. The correlation between dose and plasma level was poor. Most patients had valproic acid plasma levels between 55 and 100 microgram/ml. Administration of valproic acid three times a day with determination of individual plasma concentrations offers a reliable method of monitoring. Constant levels are maintained in individual patients, but there is substantial intersubject variation.
Similar articles
-
Single and chronic dose pharmacokinetic studies of sodium valproate in epileptic patients.Eur J Clin Pharmacol. 1979 Aug;16(1):23-9. doi: 10.1007/BF00644962. Eur J Clin Pharmacol. 1979. PMID: 387418 No abstract available.
-
Single dose and steady state pharmacokinetics of valproic acid in adult epileptic patients.Int J Clin Pharmacol Res. 1991;11(3):137-41. Int J Clin Pharmacol Res. 1991. PMID: 1809700
-
[Problems in serum-level determination during valproic acid therapy].Arzneimittelforschung. 1977;27(6):1215-21. Arzneimittelforschung. 1977. PMID: 332187 Clinical Trial. German.
-
Therapeutic monitoring of valproic acid.Ther Drug Monit. 1980;2(1):61-71. doi: 10.1097/00007691-198001000-00008. Ther Drug Monit. 1980. PMID: 6820201 Review.
-
[Valproic acid in the treatment of epilepsy with special emphasis on serum level determination (author's transl)].Fortschr Neurol Psychiatr Grenzgeb. 1978 Jun;46(6):327-41. Fortschr Neurol Psychiatr Grenzgeb. 1978. PMID: 352872 Review. German.
Cited by
-
Absorption rate and bioavailability of valproic acid and its sodium from rectal dosage forms.Eur J Clin Pharmacol. 1980 Apr;17(4):309-15. doi: 10.1007/BF00625806. Eur J Clin Pharmacol. 1980. PMID: 6772450 Clinical Trial. No abstract available.
-
Valproate-Associated Parkinsonism: A Critical Review of the Literature.CNS Drugs. 2016 Jun;30(6):527-40. doi: 10.1007/s40263-016-0341-8. CNS Drugs. 2016. PMID: 27255404 Review.
-
Concentration-effect relationships of valproic acid.Clin Pharmacokinet. 1985 Mar-Apr;10(2):155-63. doi: 10.2165/00003088-198510020-00003. Clin Pharmacokinet. 1985. PMID: 3922659 Review.
-
Histone acetylation and histone deacetylase activity of magnesium valproate in tumor and peripheral blood of patients with cervical cancer. A phase I study.Mol Cancer. 2005 Jul 7;4(1):22. doi: 10.1186/1476-4598-4-22. Mol Cancer. 2005. PMID: 16001982 Free PMC article. Clinical Trial.
-
Possible mechanism by which the carbapenem antibiotic panipenem decreases the concentration of valproic acid in plasma in rats.Antimicrob Agents Chemother. 1998 Dec;42(12):3136-40. doi: 10.1128/AAC.42.12.3136. Antimicrob Agents Chemother. 1998. PMID: 9835504 Free PMC article.